

RESEARCH

Open Access

Co-circulation of the dengue with chikungunya virus during the 2013 outbreak in the southern part of Lao PDR

Q1 5 Viengvaly Phommanivong¹, Seiji Kanda^{1*}, Takaki Shimono¹, Pheophet Lamaningao¹, Andrew Waleluma Darcy¹,
6 Nobuyuki Mishima¹, Bounthanh Phaytanavanh² and Toshimasa Nishiyama¹

Abstract

9 **Background:** During the 2013 outbreak, 4638 infection cases and 32 deaths have been recorded in the southern
10 part of Laos. In recent years, the chikungunya virus (CHIKV) emerged in the part of the country bordering
11 Cambodia. Dengue virus (DENV) and CHIKV are transmitted by common mosquito vectors. Both diseases have
12 similar clinical presentations; therefore, CHIKV infections might go undiagnosed in DENV-endemic areas. Thus, rapid
13 detection and accurate diagnosis are crucial for differentiating between the two viruses (DENV and CHIKV). In this
14 study, we demonstrated that CHIKV and two serotypes of DENV are circulating in Laos. In addition, we encountered
15 patients that had been concurrently infected with multiple DENV serotypes or DENV and CHIKV.
16

17 **Methods:** Plasma samples were collected from 40 patients with suspected DENV infections during an outbreak
18 between July and August 2013. The reverse transcription polymerase chain reaction was performed to detect the
19 four DENV serotypes and CHIKV using specific primers. Specifically, the complete envelope gene sequences of the
20 viruses were sequenced and subjected to phylogenetic analysis.

21 **Results:** Forty acute-phase plasma samples from patients with suspected dengue infections were tested for the
22 presence of DENV viral RNA using molecular methods. Among the 40 samples, 14 samples were positive for DENV,
23 2 samples were positive for both viruses (DENV-2 and DENV-3), whereas DENV-1 and DENV-4 were not detected
24 during the study period. We also encountered 10 samples that were positive for CHIKV. Of the 10 CHIKV-positive
25 samples, 3 samples were co-infected by DENV-2, and 2 samples were co-infected by DENV-3. Phylogenetic analysis
26 revealed that the 2013 dengue outbreak in Laos involved DENV-2 genotype Asian I and DENV-3 genotype II.
27 Moreover, the Laotian CHIKV strains grouped together with those isolated during outbreaks on the Indian Ocean
28 Islands within the East Central South African genotype.

29 **Conclusions:** These findings revealed that two serotypes (DENV-2 and DENV-3) and CHIKV were detected.
30 Furthermore, infection of multiple DENV serotypes and CHIKV was also observed in the 2013 dengue outbreak. This
31 is the first documented evidence of co-infection with CHIKV and one of two DENV serotypes.

32 **Keywords:** Dengue virus, Chikungunya virus, RT-PCR, Co-infection, Outbreak, Phylogenetic analysis, Co-circulation

* Correspondence: kandas@hirakata.kmu.ac.jp

¹Department of Public Health, Kansai Medical University, 2-5-1, Shinmachi,
Hirakata-shi, Osaka 573-1010, Japan

Full list of author information is available at the end of the article

33 Background

34 DF (dengue fever) is a mosquito-borne viral disease
35 caused by the dengue virus (DENV), which belongs to
36 the Flavivirus genus, *Flaviviridae* family, and has been
37 categorized into four different serotypes (DENV-1 to
38 DENV-4). It commonly occurs in tropical and subtrop-
39 ical regions [1]. The World Health Organization (WHO
40 2009) estimates that more than 50 million dengue infec-
41 tions occur yearly, resulting in half a million cases of
42 dengue hemorrhagic fever (DHF) and 22,000 deaths,
43 mainly among children. DENV is endemic in Southeast
44 Asia, the Pacific, and the Americas [2]. However, in re-
45 cent years, the hyperendemic circulation of all four den-
46 gue serotypes has been detected in Southeast Asian
47 countries [3]. Other *Flavivirus* such as Japanese enceph-
48 alitis (JE) is also endemic, occurring in Laos [4].

49 In Laos, dengue infections exhibit a cyclical pattern, i.e.,
50 they occur approximately every 2–5 years [5]. DENV sero-
51 types responsible for such infections in Laos were first
52 confirmed in 1994, and a case involving co-infection with
53 two DENV serotypes was reported [6]. Since then, larger
54 epidemics caused by all four serotypes have occurred [7,
55 8]. DENV-1 has emerged in several provinces and caused
56 sporadic clinical cases in different areas of Laos between
57 2010 and 2011 [8]. The dominant circulating serotype
58 subsequently switched from DENV-1 to DENV-3, and
59 DENV-3 virus was the predominant DENV circulating in
60 Laos at the end of June 2012 [7]. However, while some
61 suspected cases of DENV infection were confirmed using
62 laboratory detection, other cases of dengue infection were
63 diagnosed based on clinical symptoms [9].

64 Chikungunya has been identified in more than 60 coun-
65 tries in Asia, Africa, Europe, the Americas, the Indian
66 Ocean, and Pacific Islands [10]. In 2012, in a community
67 survey, 31 % (16 of 52) cases of chikungunya virus
68 (CHIKV) infection was recorded in the southern part of
69 Laos [11]. The CHIKV is a member of the *Alphavirus*
70 genus, which belongs to the *Togaviridae* family. Infection
71 of CHIKV has similar clinical presentations with DENV
72 and co-circulates in overlapping geographic regions;
73 hence, it can be underdiagnosed in areas where the
74 DENV-endemic occurs [10]. Few studies of the molecular
75 epidemiology of serotypes/or genotypes of DENV and
76 CHIKV were reported in Laos [7, 8, 11].

77 In the present study, the specimens were screened for
78 the presence of DENV and CHIKV using the reverse
79 transcription polymerase chain reaction (RT-PCR) dur-
80 ing the 2013 outbreak of DF in southern Laos. Our
81 results highlight that CHIKV and two serotypes of
82 DENV are circulating in the southern part of Laos,
83 which shares borders with Cambodia and Thailand. In
84 addition, we encountered patients that had been concur-
85 rently co-infected with multiple DENV serotypes or
86 DENV and CHIKV.

87 Methods

88 Study sites

89 Champasak province (CPS) (610 km south of Vientiane
90 capital) lies to the southwest in Laos (Fig. 1). It shares a
91 border with Thailand to the west, Salavan, Sekong, and
92 Attapeu provinces to the north and east, and Cambodia
93 to the south. The Champasak hospital, a provincial hospi-
94 tal, is arranged in the third level of health services at
95 the national level where there is inadequate laboratory
96 facilities to diagnosis of infectious diseases.

97 Clinical characterization of patients and sample collection

98 Forty hospitalized patients and 3 additional cases (1 case
99 from Oudomsay province and 2 cases from Vientiane
100 capital) were investigated during the outbreak of DF/
101 DHF from the end of July to the beginning of August
102 2013. Forty patients, aged 5 to 65 years presented with
103 acute DENV infection at days 1–6 after the onset of
104 fever with two more of the following symptoms: head-
105 ache, myalgia, arthralgia, skin rash, and hemorrhage. All
106 of these 40 patients were diagnosed with DENV infec-
107 tion. The history of their illness and complete blood
108 counts: white blood cells (WBC), platelet counts (PLT),
109 and hematocrit (HCT), were obtained from a physician
110 at the Champasak hospital.

111 A total of 8–10 ml of whole blood samples are col-
112 lected in tubes that contained EDTA as an anticoagulant.
113 Plasma samples were separated and preserved in an
114 RNA Shield™ reagent (Zymo Research) that could pro-
115 tect from RNA degradation. These specimens were then
116 transferred to the Laboratory of Public Health depart-
117 ment, Kansai Medical University, Japan.

118 Laboratory procedures

119 The plasma samples were separated from the patients'
120 whole blood by centrifugation at 1000×g for 5 min at 4 °
121 C. A total of 200–500 µl of plasma samples were directly
122 used for the viral RNA extraction and RT-PCR. The
123 remaining plasma specimens were kept at –20 °C prior
124 to testing and were stored at –80 °C until further use.

125 RNA extraction and PCR

126 Total RNA was extracted from patient's plasma sample
127 using TRIzol® reagent (Invitrogen Inc.), according to the
128 manufacturer's protocol with the following modifica-
129 tions. Then, the extracted RNA was used to synthesize
130 first-strand cDNA with random primers and reverse
131 transcriptase (ReverTra Ace®: Toyobo) for 1 h at 42 °C
132 [12]. In the PCR analysis, the cDNA was used as a tem-
133 plate and amplified using serotype-specific primers for
134 serotypes D1 to D4 of DENV according to the method
135 of Lanciotti et al. [13] or a specific primer for CHIKV
136 [14]. The general PCR conditions were as follows: 94 °C
137 for 2 min, 98 °C for 10 s, and 54–62 °C for 30 s for 35–



Fig. 1 A map of the study area (Champasak Province, Laos)

Q3].1

138 40 cycles. After their amplification, the PCR products
 139 were electrophoresed and visualized by staining 1.5 %
 140 agarose gel with ethidium bromide, and specific bands
 141 were visualized with an ultraviolet transilluminator.

142 **Sequencing of the envelope (E) gene and E1 gene**

143 In order to identify the genotypes of DENV and CHIKV,
 144 we tried to analyze the sequences of the DENV-2, DENV-
 145 3, and CHIKV isolates detected during the screening
 146 process described above. PCR was performed by using
 147 cDNA derived from the DENV-2-, DENV-3-, or CHIKV-
 148 positive patients' samples as a template and a primer pair
 149 for each target region to amplify the complete envelope
 150 (E) gene of DENV and E1 envelope glycoprotein gene of
 151 CHIKV. The following sets of specific primers for DENV-
 152 2 (Den2-911F 5'-TGACRG CTGTCGCTCCTTCA-3',
 153 Den2-2444R 5'-CARCTCACAAYGCAACCACTATC-3',
 154 1485 bp), DENV-3 (Den3-815F 5'-GCCCTTAGGCACCC
 155 AGGGTT-3', Den3-1752R 5'-CCC CGGAAAATGCTTG
 156 TGC-3', Den3-1398F 5'-CGCAAGGAG TCACGGCT
 157 GAG-3', Den3-2539R 5'-GCCTGCAATGGCTGTTGC
 158 C-3', 1479 bp) [7], and CHIKV (Chik E1Fseq1 5'-GCT
 159 CCGCGTCCTTTACC-3', Chik E1RSeq1 5'-ATGGCG
 160 ACGCCCCCAAAGTC, 540 bp) were used for the PCR

161 amplification. The PCR amplicons were directly sequenced using the BigDye® Terminator v3.1 cycle sequencing kit (Applied Biosystems). The sequencing was performed using the following conditions: 96 °C for 1 min followed by 35 cycles of 96 °C for 10 s, 50 °C for 5 s, and 60 °C for 4 min. Sequence chromatograms for both strands were obtained using an ABI3730XL automated sequence analyzer (Applied Biosystems).

166 **Phylogenetic analysis of DENV and CHIKV**

167 The complete nucleotide sequences of the E gene of the Laotian DENV-2 (1485 bp) and DENV-3 (1479 bp) strains, and the partial nucleotide sequences of the E1 gene of CHIKV (540 bp) were aligned using ClustalW [15]. A phylogenetic tree was constructed using the maximum likelihood (ML) method. The ML analysis was performed using the General Time Reversible (GTR) model with a gamma distribution, and the proportion of invariable sites (I) was estimated by MEGA v5.2 (<http://www.megasoftware.net>) [16]. The reliability of the analysis was evaluated in a bootstrap test with 10,000 replications. Representative strains of the DENV-1 and DENV-3 serotypes were used as the outgroup taxon for the DENV-3 and DENV-2 tree, respectively.

Q5]

184 The sequence of the O'nyong-nyong virus, strain IPD
185 A234 (GenBank accession number: NC001512 and
186 AF192890), was used as an outgroup for the CHIKV tree
187 [17]. Sequences of all Laotian DENV and CHIKV are de-
188 posited in the DNA Data Bank of Japan (DDBJ) under
189 accession number LC147056-LC147057 for DENV-2,
190 LC147058-LC147061 for DENV-3, and LC147062-
191 LC147064 for CHIKV, respectively.

192 Ethics statement

193 This study was approved (No. 276/NECHR) by the Na-
194 tional Ethics Committee for Health Research, Ministry
195 of Health, Lao PDR, and the Institutional Review Board
196 of Kansai Medical University (reference no.1430). In-
197 formed consent was obtained from each participant, as
198 well as parental permission for children involved in the
199 research.

200 Results

201 Clinical features

202 All of the plasma samples were collected from patients
203 with suspected DENV infections that were treated at the
204 Champasak hospital during an outbreak of DF. Forty
205 subjects were enrolled (13 in the 5–15 years age group,
206 23 in the 16–45 years age group, and 4 in the 46–
207 65 years age group), and 22 (55 %) of them were female.
208 The median age of the patients was 20.50 years (range
209 5–65).

TI 210 As shown in Table 1, all of the patients developed a
211 fever (days 1–6) and produced positive results in the
212 tourniquet test. Nearly all of the patients (97.5 %) experi-
213 enced headaches during their hospitalization. Muscle
214 pain was present in 87.5 % of patients, and joint pain
215 (70 %) and retro-orbital pain (72.5 %) were also com-
216 mon. Digestive problems were observed in 17 (42.5 %)
217 patients. The patients' other symptoms included chills
218 (17.5 %), skin rash (15 %), bleeding from the nose or
219 gums (5 %), petechiae (5 %), and bleeding that occurred
220 within 8 days of onset (2.5 %). Seventy-nine percent of
221 the patients exhibited lower white blood cell counts
222 (leukopenia <5000/mm³). Thrombocytopenia (<100,000/
223 mm³) was observed in 34 % of cases, and 23 % of pa-
224 tients were presented with increases in their HCT levels
225 of >20 % compared with the baseline. There were no
226 deaths during the study period.

227 Screening of clinical samples by PCR

228 Detection and typing of the four DENV serotypes and
229 CHIKV in plasma samples by PCR assay using specific
230 primers for DENV serotypes 1 to 4 and CHIKV.

231 In the results of the 40 specimens, 7 (17.5 %) and 5
232 (12.5 %) were found to be positive for DENV-2 and
233 DENV-3, respectively. However, DENV-1 and DENV-4
234 were not detected in the present study. Furthermore,

Table 1 Clinical features of hospitalized patients (N = 40)

Symptoms and clinical tests	No. of patients	%	t
Symptoms			t1.3
Fever	40	100	t1.4
Headache	39	97.5	t1.5
Retro-orbital pain (eye pain)	29	72.5	t1.6
Digestive problems (nausea/vomiting)	17	42.5	t1.7
Muscle pain (myalgia)	35	87.5	t1.8
Joint pain (arthralgia)	28	70	t1.9
Chills	7	17.5	t1.10
Skin rash	6	15	t1.11
Petechiae	2	5	t1.12
Bleeding nose or gum	2	5	t1.13
Bleeding within 8 days	1	2.5	t1.14
Clinical tests			t1.15
Tourniquet test	40	100	t1.16
Leukopenia (<5000/mm ³)	30	78.9	t1.17
Thrombocytopenia (<100,000/mm ³)	13	34.2	t1.18
Elevated hematocrit (>20 % increased)	9	23.1	t1.19

DENV-2 and DENV-3 co-infection was detected in 2 235
(5 %) samples. Moreover, CHIKV was also detected in 236
10 samples (25 %). Of the 10 CHIKV-positive cases, 3 237
samples were co-infected by DENV-2 and 3 samples co- 238
infected by DENV-3, respectively. The sequences of 239
these PCR products from all positive samples were also 240
confirmed by sequencing analysis. 241

242 DNA sequencing analysis

243 Serotypes/genotypes were determined by PCR and/or se- 243
quencing analysis using forward and reverse primers of 244
the complete envelope gene of DENV-2 (Den2-911F and 245
Den2-2444R, 1485 bp) and DENV-3 (Den3-815F and 246
Den3-1752R; Den3-1398F and Den3-2539R, 1479 bp), 247
and partial E1 gene of CHIKV (Chik E1Fseq1 and Chik 248
E1RSeq1, 540 bp). Entire gene sequences of two DENV- 249
2, four DENV-3, and partial gene sequences of three 250
CHIKV were then analyzed by phylogenetic analysis. 251
The results showed that the percentage of similar among 252
the two DENV-2 was 99 %, four DENV-3 ranged from 253
90 to 97 %, CHIKV ranged from 62 to 67 % when those 254
compared to each other and to strains representative of 255
the different serotypes/genotypes available on GenBank. 256

257 Phylogenetic analysis of DENV-2

258 The complete E gene sequences of two distinct DENV 258
isolates (LAO13VTE582 and LAOCPS13C33) from the 259
2013 outbreak were determined and compared with se- 260
quences of 37 representative DENV-2 strains of each 261
genotype published in GenBank. Two strains of DENV-2 262
from Laos viruses were closely related each other and 263

F2 264 belonged to genotype Asian I (Fig. 2). The genotype
 265 Asian I consists of viruses mainly from Southeast Asia,
 266 including Thailand, Cambodia, Vietnam, China, and
 267 Myanmar. No Asian II genotype and Asian/America
 268 genotype strains were found during dengue outbreak in
 269 Laos 2013.

270 **Phylogenetic analysis of DENV-3**
 271 The DENV-3 strains isolated in the current study and
 272 previously isolated DENV-3 strains from other provinces
 273 of Laos (Laungprabang, Oudomsay, and Champasak)
 274 and Vientiane were compared with sequences of 34 rep-
 275 resentative DENV-3 strains of each genotype obtained
 276 from GenBank database. Sequences of four strains for
 277 DENV-3 from Laos were grouped together within geno-
 F3 278 type II (Fig. 3). The genotype II of DENV-3 is common
 279 in Southeast Asian countries and clusters within the
 280 viral strains from China, Myanmar, the Philippines,
 281 Bangladesh, Thailand, Cambodia, and Vietnam. The addi-
 282 tional DENV-3 isolated in Vientiane in 2013 (LAOV-
 283 TE13LN680428 and LAOVTE13LN680428) [7] belong

to genotype III (Fig. 3). No genotype I and genotypes III 284
 285 strains were found in the study period.

286 **Phylogenetic analysis of CHIKV**

287 Analysis of the partial E1 gene sequences of 19 represen-
 288 tative strains of each genotype of CHIKV published in
 289 GenBank, including sequences of three representative
 290 strains of CHIKV from Laos demonstrated that all
 291 CHIKV strains from the present study were closely relat-
 292 ed to each other and other viruses from Cambodia
 293 (isolated in 2011) [18]. All study sequences clustered to-
 294 gether with the causative CHIKV strains isolated during
 295 an epidemic in the Indian Ocean Islands and belonged
 296 to the East Central South African genotype (ECSA). The
 297 ECSA genotype consists of viral strains from Southeast
 298 Asia and other countries, including Reunion Island and
 299 Kenya (Fig. 4).

300 **Discussion**

301 In 2013, Laos experienced a major DF/DHF outbreak
 302 presented with nearly 50,000 dengue cases and 92 deaths




Fig. 2 A maximum likelihood tree constructed based on the complete envelope gene sequence of DENV-2. Each DENV-2 isolate is shown together with its country of origin followed by two digits, which indicate the year in which it was isolated, and its GenBank accession number. Two representative strains that were isolated in the present study are indicated by filled triangles. Bootstrap values of <60 % are not shown. The scale bar indicates the mean number of nucleotide substitutions per site

f2.1
 f2.2
 f2.3
 f2.4

F4





Fig. 3 A maximum likelihood tree constructed based on the complete envelope gene sequence of DENV-3. Each DENV-3 isolate is shown together with its country of origin followed by two digits, which indicate the year in which it was isolated and its GenBank accession number. Four representative strains that were isolated in the present study are indicated by filled triangles. Bootstrap values of <60 % are not shown. The scale bar indicates the mean number of nucleotide substitutions per site

303 (MOH, 2013). Because CHIKV infection has similar clinical features with DENV infection and co-circulates in overlapping geographic distributions, therefore, CHIKV may be misdiagnosed in areas where DENV endemic occur [10]. During dengue fever outbreak, the Lao medical doctor only diagnosed the dengue infections among patients. Consequently, we want to identify that these patients are really infected by dengue virus or other infectious disease. The present study showed that fever, headache, retro-orbital pain, a positive tourniquet test, and body and joint pain are common symptoms in patients that have been infected with DENV. Additionally, our data also revealed that arthralgia (joint pain) and skin rash were the most common symptoms found in CHIKV-infected patients (data not shown), and similar findings were reported by Ali et al.[19].

319 In our study, a molecular screening specific for both DENV and CHIKV infections was performed on 40 acute-phase plasma samples collected from patients with

322 suspected dengue infection in southern Laos during an outbreak between July and August 2013. DENV was detected by PCR in 30 % and CHIKV in 12.5 % of samples. Two samples (5 %) were co-infected by both viruses (DENV-2 and DENV-3), and five samples (12.5 %) were co-infected by DENV and CHIKV, respectively. Although the enrolled patients included five cases that were suffering from DHF, none of the patients died, and no cases of DENV-1 or DENV-4 were found during the study period. In our analysis of 40 samples, 52.5 % were found to be dengue-negative by RT-PCR. These samples might not have been collected during the acute phase of the infection (plasma viremia reduction) [20].

335 In Laos, the dominance serotype changes from year to year since 2010. DENV-1 was dominant in 2010 and 2011; DENV-3 was dominant in 2012 followed by DENV-2, according to the National Dengue surveillance, Lao PDR [8]. Our findings indicated that both DENV-2 (17.5 %) and DENV-3 (12.5 %) were dominant serotypes



f4.1
f4.2
f4.3
f4.4

341 circulating in southern Laos in 2013. In addition, other
342 researchers reported that DENV-3 (94 %) was dominant,
343 followed by DENV-2 (3 %) circulating virus in Vientiane
344 capital, whereas few cases of DENV-1 and DENV-4
345 (ranged from <1 to <6 %) have been recorded from May
346 2012 to December 2013 [7]. That corresponds with our
347 data; DENV-1 and DENV-4 were not detected. Concur-
348 rent infection by multiple DENV serotypes (DENV-2
349 and DENV-3) was identified during the 2013 dengue
350 outbreak in Laos. Furthermore, co-circulation of DENV-
351 2 (38.7 %) and DENV-3 (29.3 %) were also reported in
352 Thailand during dengue outbreak from 2004 to 2010
353 [21]. These findings suggested that DENV serotype 2
354 and 3 may have remained viruses in the circulation in
355 these areas for a long time or they may have been intro-
356 duced from a neighboring country such as Thailand.
357 Geographically, Laos is located nearby Thailand com-
358 pared with other countries in Southeast Asia. With the
359 increased movement and/or migration of infected people
360 within and between countries, hyperendemicity (the co-
361 circulation of multiple DENV serotypes) may be oc-
362 curred [22].
363 The first case of dual infection with DENV-1 and
364 DENV-2 was a resident in Vientiane, the capital of Laos,
365 who was presented with mild symptoms of dengue,

366 which were not severe enough to require admission [6]. 366
367 Since then, there have been no further reports of dual 367
368 DENV infections in Laos. According to the data ob- 368
369 tained in the present study, we also found that the co- 369
370 infected patients were more likely to present the DHF 370
371 including, fever, digestive trouble, skin rash, a positive 371
372 tourniquet test, leukopenia, and bleeding; these patients 372
373 needed admission to hospital during their illness. 373
374 We determined the genotypes of the isolated DENV-2 374
375 and DENV-3 viruses via phylogenetic analyses of their 375
376 complete E gene sequences. DENV-2 is categorized into 376
377 five genotypes: cosmopolitan, Asian-I, Asian-II, Asian- 377
378 American, and American [23]. 378
379 Based on complete E gene sequences, DENV-2 has 379
380 been divided into five genotypes: Cosmopolitan, Asian-I, 380
381 Asian-II, Asian-American, and American [23]. The Lao- 381
382 tian DENV-2 were collected in the 2013 outbreak from 382
383 different localities in Laos (610 km South (Champasak 383
384 province)–Central (Vientiane capital)). Sequences of 384
385 these two viruses strains of DENV-2 were closely related 385
386 within genotype Asian I (Fig. 2). The genotype Asian I 386
387 of DENV-2 isolates from Laos in 21010 and 2013 387
388 grouped together with viruses from Southeast Asian 388
389 countries, including Cambodia (2009), Thailand (2010), 389
390 Vietnam (2010 and 2011), Myanmar (2010), China 390

391 (2009), Southeast Asia (2010), and Laos (2010) [24, 25].
392 The genotype Asian I found in the current study and
393 those from Southeast Asian countries formed a mono-
394 phyletic relationship with very high support values
395 greater than 98 % are shown. We suggested that the
396 genotype Asian I of DENV-2 has remained in dominant
397 circulation in Laos for a long time since 2010 until an
398 outbreak in 2013. The genotype Asian I of DENV-2 is
399 also the predominant genotype circulating in many parts
400 of Southeast Asia, except Malaysia, Singapore, Indonesia,
401 and the Philippines [23].

402 Among the five genotypes of DENV-3 (I–V) [26], se-
403 quences of DENV-3 strains from the 2013 outbreak, to-
404 gether with other Laotian sequences collected from
405 Laungprabang, Oudomsay, and Champasak provinces
406 and Vientiane capital were grouped into the same clus-
407 ter within genotype II (Fig. 3). The Laotian DENV-3
408 genotype II isolates were most closely related to those
409 isolated from China (2013), Myanmar (2009),
410 Bangladesh (2008), the Philippines (2010), Thailand
411 (2010), Cambodia (2008), and Vietnam (2010) [25, 27].
412 All of the Laotian DENV-3 genotype II viruses obtained
413 in this study and sequences from other Southeast Asian
414 countries formed a monophyletic relationship with very
415 high values bootstrap support (>98 %). We suggested
416 that they had a single origin and have been circulating in
417 Lao PDR for a long time. Two different genotypes of
418 DENV-3 (genotype II and III) have been reported to
419 have co-circulated in Laos in 2013 [7]. Even though two
420 studies have been implemented in the same year, the
421 findings are not the same. Although our sample size is
422 small, the analysis presented in this study suggested that
423 DENV-3 genotype II is circulating in the southern parts
424 of Laos and has also invaded other parts of the country.
425 Moreover, DENV-3 genotype II is the dominant circulat-
426 ing genotype in many countries in Southeast Asia [25].

427 Despite the small number of reported cases at the Na-
428 tional dengue surveillance in the Lao PDR, and the fact
429 that our study could only identify that two (5 %) cases of
430 concurrent co-infection of DENV serotypes 2 and 3 were
431 observed, Lardo et al. reported that concurrent infec-
432 tions of dengue viruses 2 and 3 have been proposed as
433 one of contributing factors to severe dengue [28]. In the
434 present study, it is difficult to conclude that a co-
435 infected patient with two serotypes (i.e., DENV-2 and
436 DENV-3) became afflicted with a more severe form of
437 dengue (DHF/DSS) because of only two cases were ex-
438 perimented. Moreover, we did not have enough informa-
439 tion about their clinical symptoms during hospital
440 admission. In addition, the relationship between concu-
441 rent infections and severe forms of dengue (DHF/DSS)
442 requires further study.

443 On the other hand, the current chikungunya epidemic
444 in Southeast Asia is being driven by the appearance of a

strain of CHIKV that originated in Africa [29] and 445
spread to Asian countries such as Cambodia [18] and 446
Thailand [30]. At present, CHIKV is known to be circu- 447
lating in southern Laos [11] and is currently spreading 448
to other regions of the country. During the 2013 out- 449
break of DENV in Laos examined in this study, we also 450
found patients that had been infected with CHIKV. In 451
fact, CHIKV-positive patients accounted for 25 % (10/ 452
40) of patients and 12.5 % (5/40) of the patients were 453
co-infected with DENV-2 or DENV-3. Other studies 454
have already recorded a high proportion of double in- 455
fected cases with CHIKV and DENV (29 % from New 456
Delhi, India, 12.4 % from West Bengal, India, and 37 457
cases from Gabon) [31, 32]. Detection of double infec- 458
tion of CHIKV and DENV in this study demonstrated 459
the probability that many chikungunya cases may go 460
misdiagnosed in areas where two viruses coexist [10]. In 461
Laos, a diagnosis of dengue and chikungunya infection 462
was based on patient's clinical symptoms and in general 463
samples were not checked by serological test such as a 464
rapid test. In this study, we did not perform the virus 465
isolation from samples. 466

Phylogenetic analysis divided CHIKV isolates into 467
three distinct genotypes based on their geographic ori- 468
gins: the West African (Waf) genotype, East/Central/ 469
South African (ECSA) genotype, and Asian genotype 470
[33]. Our findings demonstrated that the partial E1 gene 471
sequences of the Laotian CHIKV strains clustered to- 472
gether with homologous strains from Indian Ocean 473
CHIKV outbreaks within the ECSA genotype. All of 474
these Laotian CHIKV strains were closely related to the 475
CHIKV strains that caused outbreaks in Cambodia, but 476
not high bootstrap support values below 70 (Fig. 4) [18] 477
and clustered together with other isolates from recent 478
outbreaks in Asian countries (Thailand, Myanmar, 479
China, Cambodia, Malaysia, Sri Lanka, and India) [18, 480
30, 34]. A high degree of sequence similarity between 481
the Laotian and Cambodian strains and the fact that the 482
Cambodian CHIKV outbreak occurred in 2011 where 483
sharing borders with southern Laos and data from com- 484
munity survey [11], we suggested that CHIKV ECSA 485
genotype is still endemic or is continuously reintroduced 486
to the area and has invaded various regions of Laos. 487

488 Conclusions

489 Dengue is still a prevalent mosquito-borne disease in
490 Laos. Molecular detection and serotyping of dengue and
491 chikungunya were carried out on acute-phase plasma
492 samples that were collected during the 2013 dengue
493 fever outbreak from Laos. Our data suggested that the
494 identification of concurrent infection with two serotypes
495 (DENV-2 and DENV-3) and co-infections with CHIKV
496 and two DENV serotypes have been confirmed during
497 the 2013 outbreak. Furthermore, our study indicated

498 that the occurrence of DENV and CHIKV co-infections
 499 occurred in areas where these two viruses co-circulated.
 500 This is the first study to report on patients that had been
 501 co-infected with CHIKV and one of two DENV serotypes
 502 in Laos. These findings from our study will be helpful in
 503 the mitigation of priority actions such as improving sur-
 504 veillance and timely intervention to present and future
 505 outbreak threats.

506 Acknowledgements

507 We would like to thank all the individuals who participated in the study,
 508 especially the Champasak hospital, Oudomsay hospital, and Mahosot
 509 hospital laboratory staffs for their hard work and collaboration and Dr.
 510 Sengthong Bilangkoun and Dr. Khampho Chaleuvong for their help and kind
 511 support during this study. We are grateful to Phonepasong Ayé
 512 Soukhathammavong and Jordan Donaldson for their kind assistance. We also
 513 thank Yasuko Nishimura for her valuable secretary assistance. This research
 514 was partially supported by the research grant D2 from Kansai Medical
 515 University.

516 Funding

517 This research was partially funded by the Kansai Medical University. The
 518 funders had no role in the study design, data collection and analysis,
 519 decision to publish, or preparation of the manuscript.

520 Availability of data and materials

521 Not applicable.

522 Authors' contributions

523 TN conceived the idea for the study. VP, TS, PL, AWD, and BP have been
 524 involved in collecting data. VP and AWD performed the laboratory testing.
 525 SK, TS, and PL provided the technical supervision. VP Analyzed and drafted
 526 the manuscript. SK and PL revised the manuscript for significant intellectual
 527 contribution. All authors read and approved the final manuscript.

528 Competing interests

529 The authors declare that they have no competing interests.

530 Author details

531 ¹Department of Public Health, Kansai Medical University, 2-5-1, Shinmachi,
 532 Hirakata-shi, Osaka 573-1010, Japan. ²Champasak Provincial Health
 533 Department, Ministry of Health, Champasak, Lao PDR.

534 Received: 8 March 2016 Accepted: 4 July 2016

535

Q7|Q6

536 References

- 537 1. World Health Organization. Dengue/dengue haemorrhagic fever. Available:
 538 <http://www.who.int/csr/disease/dengue/en/> [Accessed 24 May 2015]
- 539 2. Guzman M, Halstead S, Artsob H, et al. Dengue: a continuing global threat.
 540 *Nat Rev Microbiol.* 2010;8:57–16.
- 541 3. WHO/TDR. Dengue—guidelines for diagnosis, treatment, prevention and
 542 control. 2009 ed. : WHO/TDR:160. Available: [http://www.who.int/tdr/
 543 publications/training-guideline-publications/dengue-diagnosis-treatment/en/](http://www.who.int/tdr/publications/training-guideline-publications/dengue-diagnosis-treatment/en/)
- 544 4. Okello AL, Burniston S, Conlan JV, et al. Prevalence of endemic pig-
 545 associated zoonoses in Southeast Asia: a review of findings from the Lao
 546 People's Democratic Republic. *Am J Trop Med Hyg.* 2015;92:1059–66.
- 547 5. Bounpone S. Dengue situation and control in Lao PDR. Center of
 548 Malariaology, Parasitology and Entomology (CMPE) Ministry of Health, Lao
 549 PDR. 2012. p. 1–21.
- 550 6. Thongchanh S, Kazumi K, Mika S, et al. Virological study on dengue
 551 epidemic in Vientiane municipality, Lao PDR, 1994. *Jpn J Trop Med Hyg.*
 552 1995;23:121–5.
- 553 7. Lao M, Caro V, Thiberge J, et al. Co-circulation of dengue virus type 3
 554 genotypes in Vientiane capital, Lao PDR. *PLoS ONE.* 2014;9:e115569.
- 555 8. Bouaphanh K, Hannah C, Pakapak K, et al. National dengue surveillance in
 556 the Lao People's Democratic Republic, 2006–2012: epidemiological and
 557 laboratory findings. *Western Pac Surveill Response J.* 2014;5:7–13.

9. Mayxay M, Phetsouvanh R, Moore C, et al. Predictive diagnostic value of the
 558 tourniquet test for the diagnosis of dengue infection in adults. *Trop Med*
 559 *Int Health.* 2011;16:127–33. 560
10. World Health Organization. Chikungunya. 2015: fact sheet N°327, May 2015.
 561 Available: <http://www.who.int/mediacentre/factsheets/fs327/en/> [Accessed
 562 24 May 2015] 563
11. Chanthavy S, Phouthone S, Khonesavanh P, et al. Emergence of
 564 chikungunya in Moonlapamok and Khong Districts, Champassak Province,
 565 the Lao People's Democratic Republic, May to September 2012. *Western*
 566 *Pac Surveill Response J.* 2013;4:46–50. 567
12. Kanda S, Tamada Y, Yoshidome A, Hayashi J, Nishiyama T. Over-expression
 568 of bHLH genes facilitate neural formation of mouse embryonic stem (ES)
 569 cells in vitro. *Int J Dev Neurosci.* 2004;22:149–56. 570
13. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid
 571 detection and typing of dengue viruses from clinical samples by using
 572 reverse transcriptase-polymerase chain reaction. *J Clin Microbiol.* 1992;30:
 573 545–51. 574
14. Niyas KP, Abraham R, Unnikrishnan RN, et al. Molecular characterization of
 575 Chikungunya virus isolates from clinical samples and adult *Aedes albopictus*
 576 mosquitoes emerged from larvae from Kerala, South India. *Virology.* 2010;7:189.
 577
15. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity
 578 of progressive multiple sequence alignment through sequence weighting,
 579 position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.*
 580 1994;22:4673–80. 581
16. Koichiro T, P. D, Nicholas P, Glen S, Masatoshi N, Sudhir K. MEGA5: molecular
 582 evolutionary genetics analysis using maximum likelihood, evolutionary
 583 distance, and maximum parsimony methods. *Mol Biol Evol.* 2011;28:2731–9
 584
17. Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of Chikungunya
 585 and O'nyong-nyong viruses: evidence for distinct geographical lineages and
 586 distant evolutionary relationships. *J Gen Virol.* 2000;81:471–9. 587
18. Duong V, Andries AC, Ngan C, et al. Reemergence of Chikungunya virus in
 588 Cambodia. *Emerg Infect Dis.* 2012;18:2066–9. 589
19. Ali U, Isahak I, Rahman M. Chikungunya confused with dengue in Malaysia:
 590 clinical, serological and molecular perspective. *Int J Microbiol.* 2010;9:1–9.
 591
20. Centers for Disease Control and Prevention. Laboratory guidance and
 592 diagnostic testing. Available: [http://www.cdc.gov/dengue/clinicalLab/
 593 laboratory.html](http://www.cdc.gov/dengue/clinicalLab/laboratory.html) [Accessed 20 January 2016] 594
21. Pongsiri P, Themboonlers A, Poovorawan Y. Changing pattern of dengue
 595 virus serotypes in Thailand between 2004 and 2010. *J Health Popul Nutr.*
 596 2012;30:366–70. 597
22. Khawsak P, Phantana S, Chansiri K. Determination of dengue virus serotypes
 598 in Thailand using PCR based method. *Southeast Asian J Trop Med Public*
 599 *Health.* 2003;34:781–5. 600
23. Ali A, Ali I. The complete genome phylogeny of geographically distinct
 601 dengue virus serotype 2 isolates (1944–2013) supports further groupings
 602 within the cosmopolitan genotype. *PLoS ONE.* 2015;10:e0138900. 603
24. Warrilow D, Northill JA, Pyke AT. Sources of dengue viruses imported into
 604 Queensland, Australia, 2002–2010. *Emerg Infect Dis.* 2012;18:1850–7. 605
25. Huang JH, Su CL, Yang CF, et al. Molecular characterization and
 606 phylogenetic analysis of dengue viruses imported into Taiwan during
 607 2008–2010. *Am J Trop Med Hyg.* 2012;87:349–58. 608
26. King CC, Chao DY, Chien LJ, et al. Comparative analysis of full genomic
 609 sequences among different genotypes of dengue virus type 3. *Virology.* 2008;5:63.
 610
27. Guo X, Yang H, Wu C, et al. Molecular characterization and viral origin of
 611 the first dengue outbreak in Xishuangbanna, Yunnan Province, China, 2013.
 612 *Am J Trop Med Hyg.* 2015;93:390–3. 613
28. Lardo S, Utami Y, Yohan B, et al. Concurrent infections of dengue viruses
 614 serotype 2 and 3 in patient with severe dengue from Jakarta, Indonesia.
 615 *Asian Pac J Trop Med.* 2016. 616
29. Pulmanasahakul R, Roytrakul S, Auewarakul P, Smith DR. Chikungunya in
 617 Southeast Asia: understanding the emergence and finding solutions. *Int J*
 618 *Infect Dis.* 2011;15:e671–6. 619
30. Wanlapakorn N, Thongmee T, Linsuwanon P, et al. Chikungunya outbreak in
 620 Bueng Kan Province, Thailand, 2013. *Emerg Infect Dis.* 2014;20:1404–6. 621
31. Caron M, Paupy C, Grard G, et al. Recent introduction and rapid
 622 dissemination of Chikungunya virus and dengue virus serotype 2 associated
 623 with human and mosquito coinfections in Gabon, central Africa. *Clin Infect*
 624 *Dis.* 2012;55:e45–53. 625
32. Afreen N, Deeba F, Khan W, et al. Molecular characterization of dengue and
 626 chikungunya virus strains circulating in New Delhi, India. *Microbiol*
 627 *Immunol.* 2014;58:688–96. 628

Q10

Q11

629 33. Lo Presti A, Lai A, Cella E, Zehender G, Ciccozzi M. Chikungunya virus,
630 epidemiology, clinics and phylogenesis: a review. *Asian Pac J Trop Med.*
631 2014;7:925-32.
632 34. Wu D, Zhang Y, Zhouhui Q, et al. Chikungunya virus with E1-A226V mutation
633 causing two outbreaks in 2010, Guangdong, China. *Virology.* 2013;10:174.
634

UNCORRECTED PROOF

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

